FDA Report: Puberty-Blocking Drug Often Used by Transgender Youths Linked to 6,700 Deaths

Lupron, a drug prescribed for transgender children to alter hormone levels was linked to over 25,000 “reactions” and 6,370 deaths.

Lupron is also used by adults to treat prostrate cancer in men and endometriosis in women.

There have been 191 deaths reported this year by users of Lupron.

 

The Christian Post reported:

Drugs that are being used to halt puberty in gender-confused youth have been linked to thousands of adult deaths, government data show.

The Food & Drug Administration has recorded thousands of deaths associated with Lupron, a puberty-blocking drug that is routinely used to treat prostate cancer in men and endometriosis in women. Adverse complications related to its use include breast disorders, malignant neoplasms, and psychiatric and nervous disorders.

Lupron — and other drugs in its class — significantly alters the hormone levels in the body and has been documented to contribute to blood clots and other cardiovascular complications, as well as brittle bones and faulty joints.

Between 2012 and June 30 of this year, the FDA documented over 40,764 adverse reactions suffered by patients who took Leuprolide Acetate (Lupron), which is used as a hormone blocker. More than 25,500 reactions logged from 2014-2019 were considered “serious,” including 6,370 deaths.

Lupron is being prescribed off-label for use in children who have been diagnosed with gender dysphoria despite the lack of formal FDA approval for that purpose.